Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • OC-associated female sexual dysfunction (FSD) for at least 3 months but no longer than one year and willingness to continue OC use but to switch to SH T00658ID or Microgynon
- • Combined score of the sexual desire and arousal domains of the FSFI questionnaire of 18 or below at screening and baseline
- Exclusion Criteria:
- • Contraindications for oral contraceptive use, for example but not limited to: presence or history of venous or arterial thrombotic / thromboembolic events, hypertension, presence or history of severe hepatic disease
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Adelaide, South Australia, Australia
Gent, , Belgium
Leuven, , Belgium
Granada, , Spain
Wien, , Austria
Wien, , Austria
Zeltweg, , Austria
Gava, Barcelona, Spain
Barcelona, , Spain
Madrid, , Spain
Leipzig, Sachsen, Germany
Subiaco, Western Australia, Australia
Freiburg, , Germany
Bangkok, , Thailand
Prahran, Victoria, Australia
Nedlands, Western Australia, Australia
Ashfield, New South Wales, Australia
Sydney, New South Wales, Australia
St. Pölten, Niederösterreich, Austria
Graz, Steiermark, Austria
Graz, Steiermark, Austria
Wien, , Austria
Bruxelles Brussel, , Belgium
Aachen, Nordrhein Westfalen, Germany
Hamburg, , Germany
Monserrato, Cagliari, Italy
Catania, , Italy
Pavia, , Italy
Pisa, , Italy
Alicante, , Spain
Bangkok, , Thailand
Bangkok, , Thailand
Patients applied
Trial Officials
Bayer Study Director
Study Director
Bayer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials